Full text is available at the source.
Abstract
Cagrilintide-semaglutide (CagriSema) may contribute to significant weight reduction and improved glycemic control.
- CagriSema is a combination treatment that includes an amylin receptor agonist and a glucagon-like peptide-1 receptor agonist.
- It is administered subcutaneously once weekly.
- Participants with excess body fat and type 2 diabetes experienced notable weight loss.
- The treatment is associated with enhanced control of blood sugar levels.
Simplified